darunavir drv sold brand name prezista among others antiretroviral medication used treat prevent generally recommended use often used low doses ritonavir cobicistat increase darunavir may used prevention needlestick injury potential taken mouth twice common side effects include diarrhea nausea abdominal pain headache rash severe side effects include allergic reactions liver problems skin rashes toxic epidermal poorly studied pregnancy appears safe protease inhibitor pi class works blocking hiv developed pharmaceutical company tibotec darunavir named arun k ghosh chemistry professor discovered molecule university illinois approved food drug administration fda june world health organizations list essential available generic fixeddose combination medication darunavircobicistat prezcobix rezolsta available single darunavir office aids research advisory council dhhs recommended treatment option adults adolescents regardless whether received hiv treatment study patients never received hiv treatment darunavir effective lopinavirritonavir weeks oncedaily approved fda october people previously treated antiretrovirals darunavir cure indicated treatment human immunodeficiency virus infection adults children three years age older coadministered ritonavir combination antiretroviral darunavir generally well tolerated people rash common side effect common side effects diarrhea headache abdominal pain constipation vomiting darunavir also cause allergic reactions people allergic ritonavir also reaction high blood sugar diabetes worsening diabetes muscle pain tenderness weakness increased bleeding people hemophilia reported patients taking protease inhibitor medicines like changes body fat seen patients taking medicines hiv including loss fat legs arms face increased fat abdomen internal organs breast enlargement fatty lumps back neck cause longterm health effects conditions darunavir may interact medications commonly taken people hivaids antiretrovirals antacids proton pump inhibitors receptor st johns wort may reduce effectiveness darunavir increasing breakdown darunavir metabolic enzyme darunavir nonpeptidic inhibitor protease pr lodges active site pr number hydrogen developed increase interactions protease resistant protease mutations kd dissociation constant x darunavir much stronger interaction pr dissociation constant protease strong interaction comes increased hydrogen bonds darunavir backbone pr active site figure darunavirs structure allows create hydrogen bonds pr active site pis developed approved furthermore backbone protease maintains spatial conformation presence darunavir interacts stable portion protease prpi interaction less likely disrupted chemical activity protease depends two residues active site one copy darunavir interacts catalytic aspartates backbone active site hydrogen bonds specifically binding residues asp asp asp gly figure interaction prevents viral replication competitively inhibits viral polypeptides gaining access active site strongly binds enzymatic portions us uk healthcare costs estimated lower boosted darunavir investigatorselected control protease inhibitors treatmentexperienced darunavir approved use united states june use european union february citations development firstgeneration clinical inhibitors founded creating proteaseligand interactions hydrogen bonding hydrophobic first hiv protease inhibitor approved fda saquinavir designed target wildtype however inhibitor longer effective due resistancecausing mutations protease structure hiv genome high plasticity able become resistant multiple protease since saquinavir fda approved several pis including httpsenwikipediaorgwikidarunavir